JOP20220017A1 - مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7 - Google Patents

مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7

Info

Publication number
JOP20220017A1
JOP20220017A1 JOP/2022/0017A JOP20220017A JOP20220017A1 JO P20220017 A1 JOP20220017 A1 JO P20220017A1 JO P20220017 A JOP20220017 A JO P20220017A JO P20220017 A1 JOP20220017 A1 JO P20220017A1
Authority
JO
Jordan
Prior art keywords
potassium channel
alcohol derivatives
channel openers
compounds
potassium channels
Prior art date
Application number
JOP/2022/0017A
Other languages
English (en)
Inventor
Shu Hui Chen
Debasis Das
Rottl?Nder
Anette Graven Sams
Krestian Larsen
Jian Hong
Xiaofang Wang
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of JOP20220017A1 publication Critical patent/JOP20220017A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات جديدة حيث تنشط قنوات البوتاسيوم Kv7. يتم توجيه سمات منفصلة من الاختراع إلى تركيبات صيدلانية تشتمل على المركبات المذكورة واستخدامات المركبات لعلاج اضطرابات مستجيبة لتنشيط قنوات البوتاسيوم Kv7.
JOP/2022/0017A 2019-08-02 2020-07-30 مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7 JOP20220017A1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
JOP20220017A1 true JOP20220017A1 (ar) 2023-01-30

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0017A JOP20220017A1 (ar) 2019-08-02 2020-07-30 مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7

Country Status (18)

Country Link
EP (1) EP4007634A1 (ar)
JP (1) JP2022543203A (ar)
KR (1) KR20220041084A (ar)
CN (1) CN114206830A (ar)
AU (1) AU2020325517A1 (ar)
BR (1) BR112021006324A2 (ar)
CA (1) CA3148719A1 (ar)
CL (1) CL2022000221A1 (ar)
CO (1) CO2022000080A2 (ar)
CR (1) CR20220028A (ar)
DO (1) DOP2022000026A (ar)
EC (1) ECSP22008993A (ar)
IL (1) IL290193A (ar)
JO (1) JOP20220017A1 (ar)
MX (1) MX2022001063A (ar)
PE (1) PE20220345A1 (ar)
WO (1) WO2021023617A1 (ar)
ZA (1) ZA202109598B (ar)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290167A1 (en) 2000-05-26 2003-03-12 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
AU2001268303A1 (en) 2000-06-11 2001-12-24 Du Pont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
EA017915B1 (ru) 2006-02-07 2013-04-30 Х. Лундбекк А/С Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
EA201070189A1 (ru) 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
HUE063567T2 (hu) * 2018-02-20 2024-01-28 H Lundbeck As Alkoholszármazékok mint KV7 káliumcsatorna nyitók

Also Published As

Publication number Publication date
ZA202109598B (en) 2024-04-24
AU2020325517A1 (en) 2022-02-24
CN114206830A (zh) 2022-03-18
CO2022000080A2 (es) 2022-01-17
KR20220041084A (ko) 2022-03-31
DOP2022000026A (es) 2022-03-31
MX2022001063A (es) 2022-02-14
EP4007634A1 (en) 2022-06-08
CL2022000221A1 (es) 2022-10-07
IL290193A (en) 2022-03-01
CR20220028A (es) 2022-03-02
WO2021023617A1 (en) 2021-02-11
BR112021006324A2 (pt) 2022-02-15
JP2022543203A (ja) 2022-10-11
ECSP22008993A (es) 2022-03-31
PE20220345A1 (es) 2022-03-14
CA3148719A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
EP4241843A3 (en) Alcohol derivatives as kv7 potassium channel openers
EA201790806A1 (ru) Иммунорегулирующие средства
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2015012056A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
MX2018014114A (es) Derivados del sobetiroma.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2019006920A (es) Derivados de la espiropiperidina.
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
JOP20220017A1 (ar) مشتقات كحول على هيئة عوامل فتح قناة بوتاسيوم Kv7
AU2018279184A1 (en) Anti-TrkB antibodies
MX2021015742A (es) Moduladores del receptor de nmda.
MX2022001805A (es) Formulaciones de anticuerpos anti-esclerostina.
JOP20210332A1 (ar) عقاقير أولية لمعدلات المستقبل nmda
WO2020086650A3 (en) Novel compounds
MX2021011364A (es) Inhibidores del canal de potasio novedosos.
MX2023003306A (es) Inhibidores del canal de potasio novedosos.
GB2553686A (en) Ethynylxanthines, preparation and use as calcium ion channel modulators
MX2021013455A (es) Extracto de agrimonia como agente anticontaminante.
PH12019500801A1 (en) Structures and mechanism for the design of highly potent glucocorticoids
EA202091327A1 (ru) Макроциклические соединения для лечения заболеваний
EA201991835A1 (ru) 2-гетероарил-3-оксо-2,3-дигидропиридазин-4-карбоксамиды для лечения злокачественного новообразования
BR112017008568A2 (pt) agentes imunorregulatórios